Trial Outcomes & Findings for Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention (NCT NCT00618436)
NCT ID: NCT00618436
Last Updated: 2014-04-07
Results Overview
This was the number of patients in each group who demonstrated seizure activity during the course of the study
COMPLETED
PHASE4
52 participants
Duration of study, up to 6 months after the injury
2014-04-07
Participant Flow
Participant milestones
| Measure |
Levetiracetam
This group will receive treatment with Levetiracetam.
|
Phenytoin
This group will receive treatment with Phenytoin.
|
|---|---|---|
|
Overall Study
STARTED
|
34
|
18
|
|
Overall Study
COMPLETED
|
34
|
18
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
Baseline characteristics by cohort
| Measure |
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
|
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
|
Total
n=52 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
44 years
n=99 Participants
|
35 years
n=107 Participants
|
42.5 years
n=206 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=99 Participants
|
5 Participants
n=107 Participants
|
13 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
26 Participants
n=99 Participants
|
13 Participants
n=107 Participants
|
39 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
34 participants
n=99 Participants
|
18 participants
n=107 Participants
|
52 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Duration of study, up to 6 months after the injuryThis was the number of patients in each group who demonstrated seizure activity during the course of the study
Outcome measures
| Measure |
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
|
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
|
|---|---|---|
|
Seizure Incidence
|
5 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: at discharge; 3 and 6 months following injuryPopulation: All patients
This is an 8 point validated scale that measures disability after brain injury. It is assessed through an in person exam or by phone interview at hospital discharge, 3 months and 6 months after injury. The categories are: 1 = dead; 2 = vegetative state; 3 = severe disability, low level; 4 = severe disability, high level; 5 = moderate disability, low level; 6 = moderate disability, high level; 7 = good recovery - low level; 8 = good recovery - high level. Specific questions and activities are assessed to determine into which category the patient falls.
Outcome measures
| Measure |
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
|
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
|
|---|---|---|
|
Extended Glasgow Outcome Score
At Discharge
|
2 units on a scale
Interval 1.0 to 4.0
|
2 units on a scale
Interval 1.0 to 3.0
|
|
Extended Glasgow Outcome Score
At 3 months
|
3 units on a scale
Interval 1.0 to 7.0
|
3 units on a scale
Interval 1.0 to 5.0
|
|
Extended Glasgow Outcome Score
At 6 months
|
3 units on a scale
Interval 1.0 to 8.0
|
3 units on a scale
Interval 1.0 to 7.0
|
SECONDARY outcome
Timeframe: Discharge; 3 and 6 months following injuryPopulation: All patients
The Disability rating scale (DRS) is frequently used in the rehabilitation literature as a measure of disability. It is a reliable, easily performed test that assesses 8 items (eye opening, verbalization, motor response, feeding, toileting, grooming, level of functioning, employability), and assigns each a numerical score ranging from 0 - 5 based on the category. The domains these 8 items are felt to assess include: alertness, cognition for self-care, dependence, and psychosocial adaptability. The scoring range is from 0-30, with increasing disability levels assigned to higher numerical values. The total DRS is then dichotomized into favorable (disability = none, mild, partial or moderate disability) and unfavorable (disability = moderately severe, severe, extremely severe, vegetative state, extreme vegetative state, death) outcomes. A DRS score of 0-6 was favorable, with any score greater than 6 categorized as unfavorable.
Outcome measures
| Measure |
Levetiracetam
n=34 Participants
This group will receive treatment with Levetiracetam.
|
Phenytoin
n=18 Participants
This group will receive treatment with Phenytoin.
|
|---|---|---|
|
Disability Rating Scale (DRS)
At Discharge
|
24 units on a scale
Interval 7.0 to 30.0
|
23 units on a scale
Interval 7.0 to 30.0
|
|
Disability Rating Scale (DRS)
At 3 months
|
15 units on a scale
Interval 0.0 to 30.0
|
13 units on a scale
Interval 5.0 to 30.0
|
|
Disability Rating Scale (DRS)
At 6 months
|
17 units on a scale
Interval 0.0 to 30.0
|
9 units on a scale
Interval 0.0 to 30.0
|
SECONDARY outcome
Timeframe: discharge; 3 and 6 months following injuryOutcome measures
Outcome data not reported
Adverse Events
Levetiracetam
Phenytoin
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place